Patents Assigned to REACTION BIOLOGY CORP.
  • Histone deacetylase inhibitors and methods for use thereof
    Patent number: 10011611
    Abstract: The present invention relates to methods of modulating (for example inhibiting) activity of histone deacetylases (HDACs) and/or treating HDACs-associated diseases including, for example, cancers, inflammatory disorders, neurodegenerative disorders, etc. The invention also provides novel compounds and compositions thereof, methods of preparation of the same, as well as methods of use of the same for inhibition of HDACs and/or treatment of HDAC-associated diseases.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: July 3, 2018
    Assignee: REACTION BIOLOGY CORP.
    Inventors: Haiching Ma, Yuren Wang
  • Selective kinase inhibitors
    Patent number: 8592415
    Abstract: The present invention relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising contacting the JAK3 with a compound of Formula I: or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present invention further provides novel compounds and compositions as well as their methods of preparation and use of the same as JAK3 inhibitors in the treatment of JAK3-associated diseases including, for example, inflammatory and autoimmune disorders.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: November 26, 2013
    Assignees: Reaction Biology Corp., Synerga Limited
    Inventors: Haiching Ma, Sorin Vasile Filip, Matthew Alexander Henry, James Alexander Dolan, Bartosz Dietrich
  • SELECTIVE KINASE INHIBITORS
    Publication number: 20110071149
    Abstract: The present invention relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising contacting the JAK3 with a compound of Formula I: or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present invention further provides novel compounds and compositions as well as their methods of preparation and use of the same as JAK3 inhibitors in the treatment of JAK3-associated diseases including, for example, inflammatory and autoimmune disorders.
    Type: Application
    Filed: February 11, 2010
    Publication date: March 24, 2011
    Applicants: REACTION BIOLOGY CORP., SYNERGA LIMITED
    Inventors: Haiching MA, Sorin Vasile FILIP